Mayo Clinic and the Translational Genomics Research Institute (TGen)
are helping launch a national clinical trial that will apply the latest
in precision medicine to treat advanced melanoma skin cancer.
The study leverages advances in genomics, informatics, and health
information technology, yielding more precise medical treatments for
patients with this devastating disease.
Sponsored by
Stand Up to Cancer (SU2C) and the Melanoma Research Alliance. These
clinical trials are the culmination of nearly four years of research
under an SU2C Melanoma Dream Team grant.
Mayo Clinic and TGen researchers have a long history of innovative
research into improving treatments for patients with metastatic
melanoma. This new clinical trial represents the next generation of
precision medicine for this disease.
The clinical trials, which will enroll patients lacking a
particular genetic mutation for whom immune therapy did not work or was
not an option, uses the latest molecular sequencing techniques to best
match targeted drugs to the unique genetic alterations present in tumors
missing the BRAF mutation. The study will evaluate if using this
precision therapy approach improves outcomes over current treatments.
The clinical trials for the project, titled Stand Up To Cancer
Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using
Molecularly-Guided Therapy for Patients with BRAF wild-type (BRAFwt)
Metastatic Melanoma, is being lead by Yale University and includes seven
other institutions:
No comments:
Post a Comment